These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 2513430

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [The loss of androgen-dependency and its molecular mechanism].
    Sato B, Nakamura N, Nonomura N, Matsumoto K.
    Gan No Rinsho; 1989 May; Spec No():261-7. PubMed ID: 2689666
    [No Abstract] [Full Text] [Related]

  • 5. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN, Schröder FH.
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
    Baretton GB, Klenk U, Diebold J, Schmeller N, Löhrs U.
    Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hormonal therapy of prostate cancer: current concepts and future prospects.
    Smith JA.
    Clin Ther; 1988 May; 10(3):281-6. PubMed ID: 3078908
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB, Isaacs JT.
    Cancer Res; 1997 Mar 15; 57(6):1054-7. PubMed ID: 9067270
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evolution of the androgen receptor pathway during progression of prostate cancer.
    Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G.
    Cancer Res; 2006 May 15; 66(10):5012-20. PubMed ID: 16707422
    [Abstract] [Full Text] [Related]

  • 16. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ.
    Cancer Res; 2004 Aug 01; 64(15):5489-95. PubMed ID: 15289359
    [Abstract] [Full Text] [Related]

  • 17. [Hormonal treatment in cancer of the prostate].
    Boccon-Gibod L.
    Rev Prat; 1987 Feb 01; 37(7):386-90. PubMed ID: 3823774
    [No Abstract] [Full Text] [Related]

  • 18. Delayed hormonal therapy in advanced prostatic cancer.
    Zungri E, Salvador J, Chéchile G, Diaz I, Martinez E.
    Prog Clin Biol Res; 1987 Feb 01; 243B():441-7. PubMed ID: 3659038
    [No Abstract] [Full Text] [Related]

  • 19. Hormone-dependence of prostatic cancer and principles of androgen deprivation.
    Neumann F.
    Arch Ital Urol Androl; 1993 Dec 01; 65(6):633-45. PubMed ID: 8312946
    [No Abstract] [Full Text] [Related]

  • 20. Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens.
    Thompson VC, Morris TG, Cochrane DR, Cavanagh J, Wafa LA, Hamilton T, Wang S, Fazli L, Gleave ME, Nelson CC.
    Prostate; 2006 Dec 01; 66(16):1698-709. PubMed ID: 16998820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.